KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial.

Seung-Hwan Lee, Kyung Ah Han, Eun-Gyoung Hong, Jun Goo Kang, Choon Hee Chung, Jong Chul Won, Eon Ju Jeon, Jung-Hwan Cho, Ho Chan Cho, Sin Gon Kim, Eun Seok Kang, So Hun Kim, Hae Jin Kim, In-Kyung Jeong, Sung Wan Chun, Young Min Cho

Diabetes Obes Metab 28(3) 2027-2037

PMID41417560
PMCIDPMC12890737
DOI10.1111/dom.70386
发表日期2025-12-19
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。
摘要

摘要

AIM: This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add-on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. MATERIALS AND METHODS: A randomised, double-blind, multicentre, therapeutic confirmatory, phase 3 clinical trial was conducted in 172 patients with T2DM. Participants with glycosylated haemoglobin (HbA1c) levels 7%-10% receiving sitagliptin and metformin were randomised 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. The primary endpoint was the change in HbA1c from baseline to week 24. RESULTS: After 24 weeks of treatment, HbA1c levels were significantly decreased in the empagliflozin 10 and 25 mg group versus the placebo group; the adjusted mean differences with empagliflozin 10 and 25 mg versus placebo were -0.7% (95% CI -1.0, -0.4; p <.0001) and -0.8% (95% CI -1.1, -0.5; p <.0001), respectively. Fasting plasma glucose levels were also significantly decreased in both empagliflozin groups compared to the placebo group (both p <.0001). More patients reached HbA1c <7% or <6.5% after 24 weeks in the empagliflozin 10 and 25 mg groups versus the placebo group (both p <.05). Efficacy was maintained in the empagliflozin groups during a 28-week extension period. Empagliflozin add-on was associated with improvements in albuminuria and body weight. The incidence of adverse events was similar across groups; add-on empagliflozin was well tolerated. CONCLUSIONS: These results suggest that coadministration of empagliflozin safely improves glycemic control in Korean patients with T2DM uncontrolled by sitagliptin and metformin.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Patient disposition.
非 KM Figure
FIGURE 2FIGURE 2 Changes in glycemic control over time: (A) Mean HbA1c from baseline to 52 weeks. (B) Mean fasting plasma glucose (FPG) from baseline to 52 weeks. Error bars are standard deviation (SD) of the mean. a Significant change compared to placebo ( p <.0001).
非 KM Figure
FIGURE 3FIGURE 3 Proportion of patients achieving HbA1c less than 7.0% or 6.5% at 24 and 52 weeks.
非 KM Figure